Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes
Journal of Allergy and Clinical Immunology · 2024
DOI: 10.1016/j.jaci.2023.08.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Laura Polivka und 56 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Reference Center for Genodermatoses (MAGEC), AP-HP, Necker-Children's Hospital, Paris Centre University, Paris, France; CE…. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Anaphylaxis, Mastocytosis. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Ministère des Affaires Sociales et de la Santé, European Commission.
Abstract (Originalsprache)
BACKGROUND: Mastocytosis and monoclonal mast cell (MC) activation syndrome (MMAS) are heterogeneous conditions characterized by the accumulation of atypical MCs. Despite the recurrent involvement of KIT mutations, the pathophysiologic origin of mastocytosis and MMAS is unclear. Although hereditary α-tryptasemia (HαT, related to TPSAB1 gene duplication) is abnormally frequent in these diseases, it is not known whether the association is coincidental or causal. OBJECTIVE: We evaluated the prevalence of HαT in all mastocytosis subtypes and MMAS and assessed the pathophysiologic association with HαT. METHODS: Clinical data, laboratory data, KIT mutations, TPSAB1 duplication (assessed by droplet digital PCR), and HαT prevalence were retrospectively recorded for all patients with mastocytosis and MMAS registered in the French national referral center database and compared to a control cohort. To increase the power of our analysis for advanced systemic mastocytosis (advSM), we pooled our cohort with literature cases. RESULTS: We included 583 patients (27 with MMAS and 556 with mastocytosis). The prevalence of HαT in mastocytosis was 12.6%, significantly higher than in the general population (5.7%, P = .002) and lower than in MMAS (33.3%, P = .02). HαT+ patients were more likely to have anaphylactic reactions and less likely to have cutaneous lesions than HαT- patients (43.0% vs 24.4%, P = .006; 57.7% vs 75.6%, respectively, P = .006). In the pooled analysis, the prevalence of HαT was higher in advSM (11.5%) than in control cohorts (5.2%, P = .01). CONCLUSION: Here we confirm the increase incidence of anaphylaxis in HαT+ mastocytosis patients. The increased prevalence of HαT in all subtypes of systemic mastocytosis (including advSM) is suggestive of pathophysiologic involvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Reference Center for Genodermatoses (MAGEC), AP-HP, Necker-Children's Hospital, Paris Centre University, Paris, France; CEREMAST, the Imagine Institute, INSERM U1163, AP-HP, Necker-Children's…
- CEREMAST, the Imagine Institute, INSERM U1163, AP-HP, Necker-Children's Hospital, Paris Centre University, Paris, France.
- CEREMAST, the Department of Dermatology, Hôpital Larrey, CHU Toulouse, Toulouse, France.
- CEREMAST, the Department of Dermatology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
- CEREMAST, the Imagine Institute, INSERM U1163, AP-HP, Necker-Children's Hospital, Paris Centre University, Paris, France; CEREMAST, the Department of Hematology, Necker-Children's Hospital, AP-HP, Paris Centre Universit…
- Department of Bioinformatics, Necker-Children's Hospital, AP-HP, Paris Centre University, Imagine Institute, INSERM U1163, Paris, France.
Förderung
- Institut National de la Santé et de la Recherche Médicale
- Ministère des Affaires Sociales et de la Santé
- European Commission
- Fondation Bettencourt Schueller
- Agence Nationale de la Recherche
Zitieren
APA
Polivka, L., Madrange, M., Bulai-Livideanu, C., Barete, S., Ballul, T., Neuraz, A., Greco, C., Agopian, J., Brenet, F., Dubreuil, P., Burdet, C., Lemal, R., Tournilhac, O., Terriou, L., Launay, D., Bouillet, L., Gourguechon, C., Damaj, G., Frenzel, L., …, & CEREMAST network (2024). Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.08.015
Vancouver
Polivka L, Madrange M, Bulai-Livideanu C, Barete S, Ballul T, Neuraz A, et al. Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2023.08.015
BibTeX
@article{Polivka2024,
author = {Polivka, Laura and Madrange, Marine and Bulai-Livideanu, Cristina and Barete, Stéphane and Ballul, Thomas and Neuraz, Antoine and Greco, Celine and Agopian, Julie and Brenet, Fabienne and Dubreuil, Patrice and Burdet, Charles and Lemal, Richard and Tournilhac, Olivier and Terriou, Louis and Launay, David and Bouillet, Laurence and Gourguechon, Clément and Damaj, Ghandi and Frenzel, Laurent and Meni, Cécile and Bouktit, Hassiba and Collange, Anne Florence and Gaudy-Marqueste, Caroline and Gousseff, Marie and Le Mouel, Edwige and Hamidou, Mohamed and Neel, Antoine and Ranta, Dana and Jaussaud, Roland and Guilpain, Philippe and Canioni, Danielle and Molina, Thierry Jo and Bruneau, Julie and Lhermitte, Ludovic and Garcelon, Nicolas and Javier, Rose-Marie and Pelletier, Fabien and Castelain, Florence and Retornaz, Frederique and Cabrera, Quentin and Zunic, Patricia and Gourin, Marie Pierre and Wierzbicka-Hainaut, Ewa and Viallard, Jean François and Lavigne, Christian and Hoarau, Cyrille and Durieu, Isabelle and Heiblig, Maël and Dimicoli-Salazar, Sophie and Torregrosa-Diaz, Jose Miguel and Soria, Angèle and Arock, Michel and Lortholary, Olivier and Bodemer, Christine and Hermine, Olivier and Rossignol, Julien and CEREMAST network, CEREMAST network},
title = {Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
doi = {10.1016/j.jaci.2023.08.015}
}
EUVIMED